Completed EARLY_PHASE1 INTERVENTIONAL 2-arm NCT05780216

Mindfulness and Psychedelics

Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced Meditators

Sponsor: Milan Scheidegger

Conditions Healthy Participants

Interventions DMT + harmine Placebo

Updated 5 times since 2023 Last updated: Sep 19, 2023 Started: Feb 20, 2023 Primary completion: Aug 5, 2023 Completion: Sep 15, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05780216, this EARLY_PHASE1 trial focuses on Healthy Participants and remains completed. Sponsored by Milan Scheidegger, it has been updated 5 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Oct 2023 — Jul 2024 [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed
Jun 2023 — Oct 2023 [monthly]

Recruiting EARLY_PHASE1
Apr 2023 — Jun 2023 [monthly]

Recruiting EARLY_PHASE1

First recorded

Feb 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Milan Scheidegger
University Medical Center Freiburg

Data source: Psychiatric University Hospital, Zurich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zurich, Switzerland